Updates on cardiovascular outcome trials in diabetes

Area of Science:

• Endocrinology
• Cardiology
• Pharmacology

Background:

• The Food and Drug Administration mandated cardiovascular outcome trials (CVOTs) for glucose-lowering drugs in 2008.
• Numerous CVOTs have since been conducted in high-risk diabetes patients, focusing on SGLT-2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists.

Purpose of the Study:

• To review and summarize the results of key cardiovascular outcome trials published in 2017.
• To provide context by comparing these results with earlier trials of glucose-lowering drugs.
• To offer an outlook on future developments in this field.

Main Methods:

• Review of published data from the DEVOTE, CANVAS, EXSCEL, and ACE trials.
• Analysis of cardiovascular safety and risk outcomes for specific anti-hyperglycemic agents.
• Comparative analysis with historical CVOT data.

Main Results:

• All tested anti-hyperglycemic drugs demonstrated cardiovascular safety.
• Empagliflozin, semaglutide, and liraglutide showed a reduction in cardiovascular risk.
• The DEVOTE, CANVAS, EXSCEL, and ACE trials confirmed safety for Insulin degludec, canagliflozin, once-weekly exenatide, and acarbose, respectively.

Conclusions:

• Glucose-lowering medications, particularly SGLT-2 inhibitors and GLP-1 receptor agonists, are safe for cardiovascular outcomes in high-risk diabetes patients.
• Certain agents offer significant cardiovascular risk reduction beyond glycemic control.
• Continued research and trials are essential for understanding the long-term cardiovascular impact of diabetes therapies.